Fig. 7

Injection of the Siglec-15 neutralizing antibody promoted fracture healing. All data in this figure are derived from 5-month-old C57BL/6 mice that underwent semiosteotomy at 3 months old and were treated with NP-149 (control antibody) or NP-159 (Siglec-15 neutralizing antibody 2) for 1 month after surgery. a Representative three-dimensional µCT images of the bone defect area in the mouse femurs. b Quantitative analysis of the µCT scan in a. n = 5, **P < 0.01. c Representative images of hematoxylin and eosin (HE staining (top row) and safranin O fast green (SOFG) staining (bottom row) of the bone defect in mouse femurs. d TRAP staining (top row) and immunohistological staining of osteocalcin (OCN) (brown, bottom row) in the bone defect area in mouse femurs. Quantitative analysis of the number (e) and area (f) of TRAP+ cells in the bone defect area. n = 5, **P < 0.01, ***P < 0.001. g Quantitative analysis of the number of OCN+ cells in the bone defect area. n = 5, **P < 0.01